Although we lacked treatment-level detail, accumulating evidence suggests that TP53 co-mutation in EGFR-mutant NSCLC portends inferior outcomes on EGFR TKIs [24,25,26]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.